Lv64
3165 积分 2020-11-13 加入
Strategies for delivering therapeutics across the blood–brain barrier
9分钟前
待确认
Transferrin receptor–targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA
11分钟前
待确认
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis
18小时前
待确认
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)
1天前
待确认
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
12天前
已完结
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy
12天前
已完结
Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series
12天前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
12天前
已完结
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy
12天前
已完结
Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy
12天前
已完结
皖公网安备34019202002308
